Inotuzumab Ozogamicin Market Size, Competitors Strategy, Regional Analysis and Industry Growth by Forecast to 2027
Inotuzumab ozogamicin is a monoclonal antibody that is combined with an anti-cancer chemotherapy drug. It is very useful in the treatment of a certain kind of acute lymphocytic leukemia that has not responded to the chemotherapy or has returned back. Inotuzumab ozogamicin has got approval by the FDA for adult treatments based upon R/R B-cell precursor ALL. The antibody component of Inotuzumab ozogamicin combines with CD22 receptors and they are mainly expressed on B cells. In clinical applications, Inotuzumab ozogamicin...
View full press release